BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Migraine readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Migraine\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641466-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06641466)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Women When Used for 
 Intermittent Prevention of Menstrual Migraine\nEstimated primary completio
 n: 29 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06641466
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645924-10397@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elismetrep: Phase 3 readout est. (NCT07645924)
DESCRIPTION:Elismetrep\, phase 3\, Migraine.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migr
 aine\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/elismetrep#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07645924
URL:https://assetmemo.bio/drug/elismetrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05598723-10441@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270225
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT05598723)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: BOTO
 X® vs. XEOMIN® for Chronic Migraine\nEstimated primary completion: 24 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/incobotu
 linumtoxina-xeomin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05598723
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018700-10441@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT07018700)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: A Cl
 inical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Pr
 eventing Episodic Migraine\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/incobotulinumtoxina-xeomi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 018700
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018713-10441@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT07018713)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: A Cl
 inical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Pr
 eventing Chronic Migraine\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/incobotulinumtoxina-xeomin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 18713
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04965675-10396@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT04965675)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine\nEstimated
  primary completion: 26 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04965675
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125302-10391@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05125302)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study to Ass
 ess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the
  Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05125302
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05897320-10396@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05897320)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study of E
 ptinezumab in Pediatric Participants With Episodic Migraine\nEstimated pri
 mary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05897320
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616128-1364@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:EVO756: Phase 2 readout est. (NCT07616128)
DESCRIPTION:EVO756\, phase 2\, Migraine.\nStudy: Study of EVO756 in Adults 
 With Migraine\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/evo756#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07616128
URL:https://assetmemo.bio/drug/evo756#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816367-10397@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Elismetrep: Phase 3 readout est. (NCT07816367)
DESCRIPTION:Elismetrep\, phase 3\, Migraine.\nStudy: A Study to Assess the 
 Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migrai
 ne\nEstimated primary completion: October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/elismetrep#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07816367
URL:https://assetmemo.bio/drug/elismetrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417775-10391@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT06417775)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study of Ora
 l Ubrogepant to Assess Adverse Events and Change in Disease Activity in Ad
 ult Participants With Menstrual Migraine\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ubrogepa
 nt-ubrelvy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06417775
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751497-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT07751497)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2\, Migraine.\nStudy: A Randomi
 zed\, Open-Label\, Multi-Center Study of Vestibular Migraine Prevention: R
 imegepant Versus Flunarizine Non-inferiority Study\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07751497
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127954-10391@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05127954)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Long-term Ex
 tension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets
  for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
 \nEstimated primary completion: January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05127954
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428838-10396@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT06428838)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: Eptinezumab 
 as an Adjunct to Standard of Care for Migraine in an Acute Emergency Conte
 xt\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06428838
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05711394-10367@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05711394)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study to As
 sess the Adverse Events and Change in Disease Activity of Oral Atogepant T
 ablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrain
 e\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05711394
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05164172-10396@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05164172)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or E
 pisodic Migraine\nEstimated primary completion: 30 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05164172
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674654-10397@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Elismetrep: Phase 3 readout est. (NCT07674654)
DESCRIPTION:Elismetrep\, phase 3\, Migraine.\nStudy: A Long-Term Safety Stu
 dy of Elismetrep (K-304) in the Acute Treatment of Migraine\nEstimated pri
 mary completion: June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/elismetrep#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07674654
URL:https://assetmemo.bio/drug/elismetrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729462-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20281021
DTEND;VALUE=DATE:20281022
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT07729462)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adults When Used for
  the Prevention of Chronic Migraine\nEstimated primary completion: 21 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant-
 nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07729462
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649242-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04649242)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Randomize
 d Study in Children and Adolescents With Migraine: Acute Treatment\nEstima
 ted primary completion: 9 January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04649242
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040813-9542@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Botox (onabotulinumtoxinA): Phase 3 readout est. (NCT07040813)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 3\, Migraine.\nStudy: The No
 rdic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumto
 xin A Dual Therapy Compared to CGRP mAbs Monotherapy\nEstimated primary co
 mpletion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07040813
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05156398-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT05156398)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Efficacy 
 and Safety Study of Rimegepant for the Preventative Treatment of Migraine 
 in Pediatric Subjects\nEstimated primary completion: 27 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05156398
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616194-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06616194)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adolescents With Fre
 quent Migraine\nEstimated primary completion: 26 February 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06616194
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743141-10363@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04743141)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Long-term
  Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment 
 of Migraine\nEstimated primary completion: 31 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04743141
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810505-10367@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT06810505)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study of Or
 al Atogepant Tablets to Assess Adverse Events and Change in Disease Activi
 ty To Prevent Migraine in Participants Aged 12 to 17 Years\nEstimated prim
 ary completion: March 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atogepant-qulipta#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06810505
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707949-10367@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05707949)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: Long-term Ext
 ension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatr
 ic Participants (6 to 17 Years of Age) With Migraine\nEstimated primary co
 mpletion: April 2032. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atogepant-qulipta#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05707949
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
